Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse formulation of the company’s lead candidate LP-10 for hemorrhagic cystitis. The trial has enrolled its first patients across...
Our goal is to provide physicians and patients with a novel, once-daily, low dose, oral option that can potentially transform the treatment landscape.” “HeFH affects 1 in 250 people worldwide and leads to increased risk of major adverse...
activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit www.aimimmuno.com
1L NSCLC patients. About BerGenBio ASA: BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe...
Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates...
of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for...
Triangle Park, NC-based company. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally related molecules. T3D Therapeutics' mission is to develop and commercialize T3D-959 for the treatment of...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced final results from its Phase...
vat pasteurization to ensure pathogen inactivation while protecting nutritional composition and bioactivity. For more information please visit, www.prolacta.com
Mercury Bio a New Mexico-based biotech company focused on the development of a novel new drug-delivery platform, has significantly accelerated its research timeline via a strategic collaboration with four major scientific partners throughout the...
(Libtayo®) followed by THIO has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase II trial. About MAIA Biotechnology, Inc: MAIA is a targeted therapy, immuno-oncology company focused on...
team of pharma industry veterans with deep expertise in the discovery and clinical development of novel drugs. For more information Please visit www.cytokipharma.com
manufacturing lentivirus and gamma-retrovirus vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. For more information please visit, www.virocell.com
an innovative pharmaceutical company focused on developing best-in-class pharmaceuticals. The company integrates APIs and formulations, combining generic and innovative drugs to meet global clinical needs. BGM0504 is a dual GIP/GLP-1 receptor...
fusion technology, driving advancements that promise to create a safer, healthier, and more sustainable world. For more information please visit, https://www.shinefusion.com/
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with...
in combination with fulvestrant. Once the recommended Phase 2 dose of the combination has been determined, there will be a formal evaluation of efficacy in an expansion cohort. "We are thrilled to have dosed the first patient with BTX-9341 at The...
The U.S. $749,999 contract, awarded through a highly competitive review process, supports early-stage therapeutic platform development for the Flexible and Strategic Therapeutics (FASTx) program of BARDA. This initiative aims to advance...
novel unconjugated antisense oligonucleotide (ASO) developed within AusperBio's proprietary Med-Oligo™ ASO technology platform, was designed to treat chronic hepatitis B for a functional cure. Its compelling preclinical data was highlighted at the...
immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is also approved in the U.S., Japan, China, and South Korea. About BioArctic AB: BioArctic AB...
